Evidence map›Paper›PMID 29890393›Full record

ReviewBiosensors & bioelectronics2018

Point-of-care microfluidic devices for pathogen detection.

Behzad Nasseri, Neda Soleimani, Navid Rabiee, Alireza Kalbasi, Mahdi Karimi, Michael R Hamblin

Abstract readReview
In one paragraph

Review in Biosensors & bioelectronics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Advances in biosensors for bacterial detection and identification.World journal of microbiology & biotechnology · 2025
    Review
  6. Review
  7. Rapid Detection ofBiosensors · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Behzad NasseriDepartments of Microbiology and Microbial Biotechnology and Nanobiotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran; Chemical Engineering Deptartment and Bioengineeing Division, Hacettepe University, 06800 Beytepe, Ankara, Turkey. Electronic address: b_nasseri@sbu.ac.ir.
Neda SoleimaniDepartments of Microbiology and Microbial Biotechnology and Nanobiotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. Electronic address: N_soleimani@sbu.ac.ir.
Navid RabieeDepartment of Chemistry, Shahid Beheshti University, Tehran, Iran. Electronic address: nrabiee94@gmail.com.
Alireza KalbasiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: alireza_kalbasi@dfci.harvard.edu.
Mahdi KarimiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran; Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: m_karimy2006@yahoo.com.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. Electronic address: Hamblin@helix.mgh.harvard.edu.

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

The rapid diagnosis of pathogens is crucial in the early stages of treatment of diseases where the choice of the correct drug can be critical. Although conventional cell culture-based techniques have been widely utilized in clinical applications, newly introduced optical-based, microfluidic chips are becoming attractive. The advantages of the novel methods compared to the conventional techniques comprise more rapid diagnosis, lower consumption of patient sample and valuable reagents, easy application, and high reproducibility in the detection of pathogens. The miniaturized channels used in microfluidic systems simulate interactions between cells and reagents in microchannel structures, and evaluate the interactions between biological moieties to enable diagnosis of microorganisms. The overarching goal of this review is to provide a summary of the development of microfluidic biochips and to comprehensively discuss different applications of microfluidic biochips in the detection of pathogens. New types of microfluidic systems and novel techniques for viral pathogen detection (e.g. HIV, HVB, ZIKV) are covered. Next generation techniques relying on high sensitivity, specificity, lower consumption of precious reagents, suggest that rapid generation of results can be achieved via optical based detection of bacterial cells. The introduction of smartphones to replace microscope based observation has substantially improved cell detection, and allows facile data processing and transfer for presentation purposes.

Indexed as

Microfluidic Analytical TechniquesBacterial InfectionsBiosensing TechniquesHumansLab-On-A-Chip DevicesPoint-of-Care SystemsReproducibility of ResultsVirus DiseasesBiomarkers of infectionInfectious microorganismsLab-on-a-chip diagnosisLow resource environmentsMicrofluidics-based assaysMicropattern soft lithographyPoint-of-care devicesSmart-phone based sensors

Identifiers

PMID29890393
PMCPMC6082696

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.